الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 120 |  |  |
| | | from | 120 | | |
Abstract
Antimullerian hormone (AMH), also known as mullerian inhibiting substance (MIS), is a dimeric glycoprotein member of the transforming growth factor-â family. AMH is secreted by granulosa cells within preantral and early antral follicles, <4 mm in diameter. Its secretion decreases as the antral follicles begin to grow, and stops when the follicles are larger 8 mm in diameter, or when atresia occurs.
Several reports suggest that AMH might be a better predictor of ovarian responses to controlled ovarian hyperstimulation (COS) than traditional parameters such as age, FSH, estradiol (E 2) and inhibin B (INH-B).
A previous study has showed that the performance of AMH as a predictor of poor ovarian response was very similar to that achieved with antral follicle counts (AFC).
Previous studies have found associations between AMHs (including serum AMH and follicle fluid AMH), fertilization rate, blastocyst development, embryo quality, pregnancy outcome and live birth rate (LBR).
An association has also been found between follicle fluid AMH (FF AMH) levels and the quality of embryos in patients with polycystic ovary syndrome (PCOS).
We aimed in this study to investigate the predictive value of follicular fluid anti-Mullerian hormone (AMH) on fertilization rate (FR), implantation rate, blastocyst development, embryo quality, chemical pregnancy, clinical pregnancy and ongoing pregnancy after ICSI.
The results of the current study showed that:
1. Statistical insignificant differences in age and BMI between both low FF AMH and high FF AMH groups (p= 0.631), (p=0.231) respectively.
2. Statistical insignificant differences in Baseline (d3) serum AMH between low FF AMH and high FF AMH groups as (p=0.195).
3. Statistical insignificant differences in E2 d HCG among study groups as (p=0.420).
4. The correlation between FF E2 and FF AMH was significant indirect correlation as (r=0.409), (p< 0.001) indicating that the lower the levels of FF AMH the higher levels of FF E2.
5. Significantly higher rate of fertilization and more number of top-quality oocytes among low FF AMH compared to high FF AMH as (p=0.021), (p=0.014) respectively.
6. Significantly higher rate of embryo implantation and number of clinical pregnancies among low FF AMH compared to high FF AMH as (p<0.001), (p=0.001) respectively.
7. While there was statistical insignificant difference in number of multiple pregnancies between both groups as (p=0.884).
8. FF E2 and Clinical pregnancy had significant indirect correlations with FF AMH.
9. The correlation between clinical pregnancy and FF AMH was significant indirect correlation as (r=0.618), (p<0.001) indicating that the lower levels of AMH associated with more numbers of clinical pregnancy.
10. FF AMH had a good sensitivity and specificity for prediction of clinical pregnancy.
There were significantly higher rates of fertilization, more number of top-quality oocytes, and higher clinical pregnancy and embryo implantation rates in low FF AMH group than high FF AMH group. However, the multiple pregnancy rates were comparable and did not differ significantly between the two groups.
The FF AMH had 73.1% sensitivity and 85.3% specificity for predication of clinical pregnancy.